相关实验视频

Updated: Sep 10, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

针对G1-S检查点受损的癌症使用环林A/BRxL抑制剂

Shilpa Singh¹, Catherine E Gleason², Min Fang³

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

|August 20, 2025

概括

新的宏环通过抑制环林相互作用选择性地杀死小细胞肺癌 (SCLC) 细胞. 这些口服药物通过引发螺旋组合检查点激活来向E2F驱动的癌症.

科学领域:

癌症学
分子生物学
癌症治疗方法

背景情况:

小细胞肺癌 (SCLC) 的特征是RB1和TP53的突变,导致E2F活动失调.
虽然E2F的过度激活对细胞循环进展至关重要,但它可能会促进细胞亡,从而导致治疗的脆弱性.
针对环素-基质相互作用界面,特别是RxL基因,一直是具有挑战性的.

研究的目的:

开发针对环素RxL基因的新型细胞通透性,口服生物可用的宏环.
研究这些抑制剂在具有高E2F活性的癌细胞,包括SCLC中的疗效.
阐明这些新型抑制剂抗癌作用的分子机制.

主要方法:

开发针对cyclin A和cyclin B RxL基因的双抑制剂 (cyclin A/Bi).
选择性杀死高E2F活性的SCLC和其他癌细胞的评估.
使用基因选来识别诱导亡的机制.
研究B环素,CDK2和螺旋组合检查点的作用.
评估耐化疗SCLC患者衍生的异种移植的抗瘤活性.

主要成果:

环素A/ Bi可以选择性地杀死SCLC和其他具有高E2F活性的癌细胞.
通过循环B和CDK2依赖的螺旋组合检查点激活诱导细胞亡.
环素A/ Bi阻断了环素A- E2F和环素B- MYT1 RxL的相互作用,导致了E2F和环素B的过活化.
形成新型环林B-CDK2复合体,导致线粒细胞死亡.
在SCLC异种移植中,口服的cyclin A/ Bi表现出显著的抗瘤活性.

结论:

开发出可口生物利用的宏环 (cyclin A/ Bi),可以抑制cyclin RxL的相互作用.
通过诱导亡,Cyclin A/ Bi有效向E2F驱动的癌症,包括SCLC.
这些发现支持cyclin A/ Bi在治疗耐化疗SCLC和其他癌症方面的治疗潜力.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

The Cell Cycle Control System

The Cell Cycle Control System

The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.